Proactive Investors - Run By Investors For Investors

Motif Bio PLC chief looking to add “one or two partners during 2016”

It has been a busy few months for Motif Bio PLC (LON:MTFB), the company behind next-generation antibiotic, iclaprim, and chief executive Graham Lumsden speaks to Proactive.

The firm recently passed a major milestone when it dosed its first patient in one of two phase III clinical trials it is carrying out, and just this week announced the appointment of specialist adviser, The Fulford Group to assist with the commercialisation of the treatment.

Lumsden says the company is looking for “one or two partners during 2016” to help commercialise iclaprim globally, and that the Fulford Group, which “specialises in finding partners for companies like Motif,” will aid the firm to do this.

Meet Eco (Atlantic) Oil & Gas Ltd, Bushveld Minerals Limited, Ncondezi Energy and Hurricane Energy PLC at our event, London, 13 June 2016. Register here »
View full MTFB profile

Motif Bio Plc Timeline

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.